Loading organizations...
§ Private Profile · Oxford, Oxfordshire, United Kingdom
Ultromics is a technology company.
Ultromics develops AI-powered diagnostic solutions that integrate with echocardiography workflows to detect specific phenotypes of heart failure. Their EchoGo platform utilizes advanced pattern recognition, deep learning, and machine learning algorithms to analyze echocardiograms, identifying conditions like heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis with greater precision than traditional methods. This technology supports clinicians in making faster, more accurate diagnoses from a single image view.
The company was founded in 2017 by Ross Upton and Professor Paul Leeson, spinning out of the University of Oxford. Ross Upton, during his PhD studies in cardiovascular medicine, recognized the limitations of conventional echocardiography, which often led to missed or indeterminate diagnoses due to its subjective and time-consuming nature. This insight led him to design an algorithm with Professor Leeson to overcome these challenges, forming the basis of the EchoGo technology.
Ultromics' solutions serve clinicians and healthcare providers by streamlining diagnostic pathways for cardiovascular diseases. The company's vision is to significantly improve patient outcomes by closing critical diagnostic gaps in heart failure. They aim to accelerate early diagnosis and enable timely, effective management of cardiovascular conditions, ultimately enhancing the lives of individuals affected by heart disease.
Ultromics has raised $111.0M across 4 funding rounds.
Ultromics has raised $111.0M in total across 4 funding rounds.
Ultromics has raised $111.0M in total across 4 funding rounds.
Ultromics's investors include Victor Westerlind, Alastair Stewart, Umur Hursever, HealthQuest Capital, Sandbox Industries, BlueCross BlueShield Venture Partners, Google Ventures, Oxford Science Enterprises, Oxford University, University of Chicago Medicine, UPMC Enterprises, Vijay Barathan.
Ultromics has raised $111.0M across 4 funding rounds. Most recently, it raised $55.0M Series C in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2025 | $55M Series C | Victor Westerlind, Alastair Stewart, Umur Hursever | HealthQuest Capital, Sandbox Industries, Bluecross Blueshield Venture Partners, GV, Oxford Science Enterprises, Oxford University, University OF Chicago Medicine, UPMC Enterprises | Announced |
| Aug 1, 2021 | $33M Series B | Bluecross Blueshield Venture Partners | HealthQuest Capital, Sandbox Industries, GV, Vijay Barathan, Oxford Science Enterprises | Announced |
| Jun 17, 2020 | $10M Venture Round | Oxford Science Enterprises | Mayo Clinic | Announced |
| May 1, 2018 | $13M Series A | Oxford Science Enterprises | 24Haymarket, Andre Crawford Brunt, Dieter Spälti, GT Healthcare Capital Partners, Muang Thai Fuchsia Ventures, Neptune, RT Ventures, Tanarra Capital | Announced |
Ultromics is an AI-powered medical technology company that develops the EchoGo® platform to enhance echocardiogram analysis for early detection of complex heart diseases, particularly heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis.[1][2][4] It serves hospitals, echo labs, and health systems by integrating seamlessly into existing workflows via cloud-based DICOM processing, delivering automated reports in under 20 minutes to reduce unnecessary tests, streamline diagnostics, and enable earlier treatment—addressing the undiagnosed cases among 64 million global heart failure patients.[1][2][4] With FDA clearances, Medicare reimbursement, and recent $55M Series C funding, Ultromics shows strong growth, expanding U.S. adoption and its pipeline for additional cardiac conditions.[1]
Ultromics originated from the University of Oxford, founded in 2017 as a spin-out after Ross Upton, working with Professor Paul Leeson, developed the initial EchoGo algorithm to overcome limitations in traditional echocardiogram analysis.[1][2] The idea emerged from addressing diagnostic challenges in heart failure phenotypes like HFpEF, leveraging deep learning trained on Mayo Clinic's outcome database for single-view disease detection.[2] Early traction built through NHS partnerships and clinical studies, leading to rapid milestones: over 20 published studies, three FDA clearances (including Breakthrough Device for EchoGo® Amyloidosis in 2024 and EchoGo® Score in 2025), CE marks, and Medicare codes by 2025.[1][2]
Ultromics rides the wave of AI in medical imaging, specifically cardiology, where echocardiography limitations hinder early heart failure detection amid a global epidemic affecting 64 million.[2][4] Timing aligns with health systems combating rising cases, post-2024/2025 regulatory wins enabling scaled U.S. adoption as AI diagnostics become workflow defaults.[1] Favorable market forces include Medicare reimbursement, pharma/academic collaborations (e.g., Mayo, J&J, MedStar) for trials/biomarkers, and AI's role in reducing variability—proven in COVID mortality prediction.[5][6] It influences the ecosystem by setting standards for reimbursable AI, partnering with leaders to accelerate discoveries, and easing provider burden in overburdened systems.[1][5]
Ultromics is poised for U.S. dominance with its $55M Series C fueling hospital expansions, pipeline growth (new conditions/channels), and deeper health system ties amid AI cardiology demand.[1] Trends like outcome-linked reimbursement and collaborative AI will propel it, potentially evolving from diagnostic leader to ecosystem enabler for trials and therapies. As heart failure crises intensify, Ultromics' Oxford-honed precision could redefine early intervention, tying back to its mission of turning elusive diagnoses into scalable, life-saving defaults.[1][2]